TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Core Viewpoint - TELA Bio, Inc. has successfully closed a public offering of 14,670,000 shares of common stock, raising gross proceeds of $46 million, which will be utilized for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at$2.25 per share, with an additional option for investors to purchase pre-funded warrants at a price of $2.2499 each, allowing for the purchase of 5,800,000 shares [1]. - The offering included the full exercise of the underwriters' option to purchase additional shares [1]. - Canaccord Genuity and Lake Street Capital Markets served as joint bookrunners for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, which encompass sales and marketing, research and development, general and administrative expenses, working capital, and capital expenditures [2]. Group 3: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company that focuses on innovative soft-tissue reconstruction solutions, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [5]. - The company emphasizes the use of advanced technologies that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [5].